Study to evaluate the safety of routine diagnostic anterior chamber paracentesis (ACP) for proteomic profiling in patients with geographic atrophy (GA)
Who can participate
Age range50 Years – 89 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Male or female subjects aged between 50 and 89 years, inclusive
* For the GA cohort: Clinical diagnosis of GA secondary to AMD or dAMD in the study eye, confirmed by fundus autofluorescence imaging and spectral-domain optical coherence tomography (SD-OCT).
* For the control cohort: No clinical evidence of retinal disease in either eye.
* Best-corrected visual acuity (BCVA) of ≥20/200 in the study eye, as measured by Early Treatment Diabetic Retinopathy Study (ETDRS) charts
* Ability and willingness to provide written informed consent before any study-specific procedures.
Exclusion Criteria:
* Presence of active ocular infection or inflammation in either eye at the time of screening.
* History of intraocular surgery in the study eye within the three months preceding enrollment.
* Intraocular pressure (IOP) greater than 21 mmHg in the study eye at screening
* Use of systemic anticoagulation therapy that cannot be safely discontinued prior to ACP.
* Pregnant or nursing women.
* Known hypersensitivity or contraindication to any of the medications or procedures used in the study.